Fosun Tweaks Gland Deal Amid Limbo In India

 
• By Anju Ghangurde and Ying Huang

China’s Fosun group isn’t backing off from its $1bn-plus buyout of Gland Pharma and will now pursue a tweaked version of the original deal that technically qualifies for automatic approval under Indian rules. Whether that means smooth sailing hereon remains unclear.

Big Fish
WILL FOSUN'S ACQUISITION OF GLAND MOVE SMOOTHLY AHEAD HEREON?

More from Business

More from Scrip